AtriCure beats Q4 profit estimates

AtriCure

17/02/2026 21:09

Overview

Surgical treatment innovator's Q4 revenue rose 13.1% yr/yr

Adjusted EPS for Q4 beat analyst expectations

Adjusted EBITDA for Q4 beat analyst expectations

Outlook

AtriCure projects 2026 revenue of $600 mln to $610 mln, up 12% to 14% from 2025

Company expects 2026 adjusted EBITDA of $80 mln to $82 mln

AtriCure anticipates 2026 adjusted EPS of $0.09 to $0.15

Result Drivers

PRODUCT PERFORMANCE - Growth in Q4 revenue driven by cryoSPHERE MAX probe, AtriClip FLEX-Mini device, and EnCompass clamp

INTERNATIONAL GROWTH - International revenue increased by 15.3%, with growth in most key markets

FAVORABLE PRODUCT MIX - Gross margin increased due to a more favorable product mix

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Adjusted EPS
Beat
$0.06
-$0.10 (8 Analysts)
Q4 Adjusted EBITDA
Beat
$19.90 mln
$13.02 mln (8 Analysts)
Q4 Gross Margin
75.00%
Q4 Gross Profit
$105.30 mln
Q4 Operating Income
$2.50 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for AtriCure Inc is $54.00, about 65.4% above its February 13 closing price of $32.65

Press Release: ID:nBw1446yva

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)